Furthermore, activation of NRF2 in myeloid-derived suppressor cells reverses tumor-mediated immune suppression [19;20]; therefore, the use of an NRF2 activator in combination with targeted cancer immunotherapies may also be a promising approach to cancer treatment. Here, NFE2L2 is linked to neoplasm.